LARTRUVO
- Product NDC
- 0002-8926
- 11-digit product format
- 000028926
- Labeler code
- 0002
- Product ID
- 0002-8926_643bc3d4-ecdd-4971-b35a-369931be98b0
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- olaratumab
- Dosage form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS
- Labeler
- Eli Lilly and Company
- Application
- BLA761038
- Marketing category
- BLA
- Marketing start
- 2016-10-19
- Marketing end
- 0000-00-00
- Substance
- OLARATUMAB
- Active strength
- 10 mg/mL
- NDC exclude flag
- No
- Listing certified through
- 2020-12-31
- Current FDA listing
- Historical FDA.report record
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status.
Dataset, Scope, Product NDC table| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|
| excluded product | product | 0002-8926 | | D | Discontinued by firm | | 2026-07-31 |
| excluded package | package | 0002-8926 | 0002-8926-01 | D | Discontinued by firm | | 2026-07-31 |
Purple Book Biologic Products#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 761038 | Lartruvo | olaratumab | 351(a) | Disc | 2026-06-01 |